Infectious Diseases and Therapy

metrics 2024

Empowering discovery in infectious disease therapy.

Introduction

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Metrics 2024

SCIMAGO Journal Rank1.35
Journal Impact Factor4.70
Journal Impact Factor (5 years)4.60
H-Index45
Journal IF Without Self4.70
Eigen Factor0.01
Normal Eigen Factor1.19
Influence1.33
Immediacy Index1.10
Cited Half Life2.70
Citing Half Life5.20
JCI0.93
Total Documents846
WOS Total Citations2892
SCIMAGO Total Citations6275
SCIMAGO SELF Citations159
Scopus Journal Rank1.35
Cites / Document (2 Years)4.52
Cites / Document (3 Years)4.37
Cites / Document (4 Years)4.17

Metrics History

Rank 2024

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 20/132
Percentile 85.20
Quartile Q1

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 32/132
Percentile 75.76
Quartile Q1

Quartile History

Similar Journals

INFECTION

Pioneering Insights into Infectious Challenges
Publisher: SPRINGER HEIDELBERGISSN: 0300-8126Frequency: 6 issues/year

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

MICROBES AND INFECTION

Championing Open Access for Microbial Insights
Publisher: ELSEVIERISSN: 1286-4579Frequency: 12 issues/year

MICROBES AND INFECTION is a premier academic journal published by Elsevier, dedicated to the dynamic fields of immunology, infectious diseases, and microbiology. With a notable impact factor reflective of its high-quality research contributions, the journal is categorized in the Q2 quartile across these fields as of 2023. Based in France and operating since 1999, MICROBES AND INFECTION offers a platform for researchers, professionals, and students to disseminate and access cutting-edge findings that drive innovation and knowledge in microbial and infectious disease research. The journal is ranked impressively within the Scopus database, securing ranks such as #16 in Microbiology and #33 in Infectious Diseases, underscoring its high relevance in the scientific community. Subscribers to the journal can expect an array of articles, reviews, and original research, all designed to advance understanding and improve clinical practices in the fight against infectious agents. With its ongoing commitment to open access options, MICROBES AND INFECTION continues to foster global collaboration and information sharing in the pursuit of addressing pressing microbiological challenges.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Advancing the Frontiers of Antimicrobial Science
Publisher: AMER SOC MICROBIOLOGYISSN: 0066-4804Frequency: 12 issues/year

Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

JOURNAL OF INFECTION AND CHEMOTHERAPY

Empowering Clinicians with Cutting-edge Insights
Publisher: ELSEVIERISSN: 1341-321XFrequency: 6 issues/year

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

Archives of Clinical Infectious Diseases

Unveiling Innovations in Infectious Disease Management
Publisher: BRIEFLANDISSN: 2345-2641Frequency: 4 issues/year

Archives of Clinical Infectious Diseases is a peer-reviewed journal dedicated to advancing knowledge in the field of infectious diseases, published by BRIEFLAND in Iran. With a broad scope, it covers various aspects of cardiology, critical care, immunology, microbiology, public health, and toxicology, affirming its relevance in today's health landscape. Despite the lack of open access options, the journal maintains a strong reputation, reflected in its Q3 ranking in multiple categories within the 2023 category quartiles. The journal aims to provide a platform for researchers and practitioners to disseminate critical findings that can impact clinical practices and public health policies. Its commitment to rigorous peer review ensures that only high-quality research is published, thereby serving as an essential resource for professionals, students, and public health advocates. For those engaged in the ever-evolving world of infectious diseases, Archives of Clinical Infectious Diseases stands as a vital contribution to the medical literature.

ANTIVIRAL THERAPY

Exploring innovative therapies for viral infections.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Antibiotics-Basel

Pioneering discoveries in antibiotic management and resistance.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi

Connecting researchers to combat emerging infection challenges.
Publisher: BILIMSEL TIP YAYINEVIISSN: 1300-932XFrequency: 4 issues/year

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi, published by BILIMSEL TIP YAYINEVI, is a leading journal dedicated to the field of infection diseases and clinical microbiology. With an ISSN of 1300-932X and an E-ISSN of 2602-2842, this journal has been an established Open Access platform since 1999, allowing researchers worldwide to access critical studies and advancements without barriers. The journal aims to disseminate high-quality research articles, reviews, and case studies that address emerging challenges in infection management and microbiological practices. By fostering a collaborative environment for professionals, researchers, and students alike, Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi plays a vital role in advancing knowledge and practices within the microbiological and clinical spheres. Its commitment to open access ensures that invaluable resources are widely available, supporting the growth and development of innovation in the medical field.

CLINICAL INFECTIOUS DISEASES

Advancing the fight against infectious diseases.
Publisher: OXFORD UNIV PRESS INCISSN: 1058-4838Frequency: 24 issues/year

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

Brazilian Journal of Infectious Diseases

Pioneering research for a healthier tomorrow.
Publisher: ELSEVIER BRAZILISSN: 1413-8670Frequency: 6 issues/year

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.